Photoaffinity-based Protein Profiling Approach to Discover Estrogen Receptor/ Coactivator Inhibitors
Type of Award: Catalyst
Award Period: March 2015 - February 2017
Amount Awarded: $ 199,330.00
PI(s): Jonna Frasor, PhD, UIC; Terry Moore, PhD, UIC; Geoffrey Greene, PhD, UChicago;
Abstract: The estrogen receptor (ER) is expressed in ~75% of breast cancers. Patients who have estrogen receptor-positive (ER+) breast cancer are typically prescribed endocrine therapy, but 1/3 of these cases will fail, for various reasons. It is important to note that ER is still expressed and active in 80- 85% of these therapy-resistant cancers; thus, new ways of targeting ER in breast cancer are needed. Association of ER with coactivators is an important step in ER+ breast cancer, and we will target this interaction as a new potential therapy. Because this interaction is still involved in the majority of endocrine resistant breast cancers, this approach should work in most of these cases and could revolutionize breast cancer therapy.